{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009744","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.517437+00:00","generated_at":"2026-05-16T10:52:03.980384+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axsome reports preliminary 4Q and FY 2025 net product revenue of $196M and $638.5M, up 65% and 66% YoY","bullets":["Total preliminary 4Q net product revenue $196.0M (+65% YoY); full year $638.5M (+66% YoY).","AUVELITY net product sales: $155.1M (4Q), $507.1M (FY).","SUNOSI net product revenue: $36.7M (4Q), $124.8M (FY).","SYMBRAVO net product sales (launched June 2025): $4.1M (4Q), $6.6M (FY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009744","json":"https://secwatch.observer/filing/0001193125-26-009744.json","markdown":"https://secwatch.observer/filing/0001193125-26-009744.md","text":"https://secwatch.observer/filing/0001193125-26-009744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526009744/0001193125-26-009744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526009744/axsm-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:52:03.980384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}